Navigation Links
New antibacterials being developed to tackle MRSA superbug

A novel antibacterial medicine that kills the superbug MRSA is being developed under a new scheme launched by the Wellcome Trust. The Seeding Drug Discovery initiative is aimed at catalysing the development of new drugs in areas of unmet need.

Prolysis, an R&D company based in Oxford, has received one of three inaugural Seeding Drug Discovery awards for its new antibacterial compounds aimed at tackling life-threatening, drug-resistant infections caused by staphylococci, including MRSA.

The bacterium Staphylococcus aureus can infect wounds, including those resulting from medical procedures conducted in hospitals. It may then spread further into the body and cause serious infections such as blood poisoning. Methicillin-resistant Staphylococcus aureus, or MRSA, is a form of the bacterium that is resistant to the drug methicillin and a number of other antibiotics and tends to be more difficult to treat.

"The so-called superbug MRSA is fast becoming untreatable with the currently available antibiotics," says Dr Ted Bianco, Director of Technology Transfer at the Wellcome Trust. "We urgently need a new generation of antibacterial medicines to stop its spread through hospitals, nursing homes and the wider community."

The compounds being developed by Prolysis under the award from the Wellcome Trust block the ability of the MRSA bacteria to divide and multiply. They do this by inhibiting the function of the bacterium's FtsZ protein, which is essential for cell division. FtsZ is not found in humans so targeting a unique protein like this should reduce the likelihood of side-effects in patients. Because of the novel mode of action of the new class of compounds, the levels of resistance in the bacterial population should be extremely low if a new drug was to emerge from this programme.

"The antibiotic that we are developing is far more selective than those currently in use, targeting only staphylococcal infections," says Dr Lloyd C zaplewski, Director of Research at Prolysis. "Other, broad-spectrum antibiotics tend to kill the patient's natural bacteria, leaving them open to secondary infection by other pathogenic bacteria, for example Clostridium difficile."

Given the urgent need for new antibacterials to tackle staphylococcal infections, Dr Czaplewski believes that the research, supported by this £3.48 million, 33 month award, could result in a new medicine being fast-tracked into clinical evaluation by 2009.


'"/>

Source:Wellcome Trust


Related biology news :

1. Emergence of cancer as major cause of childhood death in developing countries is not being adequately addressed
2. When it comes to cell entry, being average has its advantages
3. Sperm stem cells closer to being like embryonic stem cells
4. Progress being made in exploring potential use of stem cells to treat heart disease
5. Nanotechnology being used to improve biocompatibility of human prosthetics and implants
6. Fat stem cells being studied as option for breast reconstruction
7. DNA layer reduces risk of reserve parts being rejected
8. Are scientists making progress in being able to regenerate bone tissue?
9. Robot-based system developed at Carnegie Mellon detects life in Chiles Atacama desert
10. Disease progression model of pancreatic cancer developed by Penn researchers
11. New HIV drug candidate developed in Sweden
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/13/2017)... 2017 According to a new market research report ... Identity Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region ... expected to grow from USD 14.30 Billion in 2017 to USD 31.75 ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is ... and 8th June 2018 in San Francisco, CA. The Summit brings together current and ... distinguished CEOs, board directors and government officials from around the world to address key ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the main ... people each year. Especially those living in larger cities are affected by air pollution ... of the most pollution-affected countries globally - decided to take action. , “I knew ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
(Date:10/10/2017)... CRUZ, Calif. , Oct. 10, 2017 ... grant from the NIH to develop RealSeq®-SC (Single Cell), ... kit for profiling small RNAs (including microRNAs) from single ... Analysis Program highlights the need to accelerate development of ... "New techniques for measuring ...
Breaking Biology Technology: